Abstract 453P
Background
In terms of the clinical outcome and bad prognosis of cancer, the elevation in IL-6 levels is correlated with disease progression. It is believed that the post-vaccination effect increases the levels of IL-6 antagonists, which can slow the growth of cancer cells.
Methods
This research was conducted out on all cancer patients at Dr. Moewardi General Hospital using an observational analytical research design with a cross-sectional study, with a total sample of 120 patients who were divided into groups that had and had not received vaccination. IL-6 levels were measured using blood samples. To identify the correlation between IL-6 levels and COVID-19 vaccination status, we did descriptive analysis and the Chi-square test to examine the data results.
Results
There were 120 respondents in total, which all were processed for the analysis. out of 99 respondents who had full vaccination records. Then, 21 respondents who did not complete their vaccination status or receive the vaccine. Breast cancer is the most common cancer type in this population, which consists of 80 women and 40 males. Then, 59 respondents had increased Il-6 levels, whereas 61 respondents had normal levels. Findings of the research showed no statistically significant relationship between IL-6 levels and vaccination status (p>0.05).
Conclusions
IL-6 levels were used to analyze the relationship between vaccination status and cancer progression, and it was shown that participants who had received immunizations had no more impact on IL-6 levels than those who had not.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rico Alfredo Hutabarat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06